Tasty beer starts with knowing what’s in your hops. Explore how online SPE makes bitter acid analysis in hops faster and more reliable.<h4>How can you detect bitter acid profiles quickly, reliably, and more sustainably?</h4>For craft brewers and beer lovers alike, a refreshing experience is all about flavor.So how can you achieve the desired bitterness in your beer? The answer is not just about the recipe. Finding the right flavor profile starts with the bitter acids present in the starting hops material.<div><div>Hops (the heart of your favorite beer) are the source of the brew’s distinctive flavor tied to bitterness and aroma.At the molecular level, bitterness is driven by <a target="_blank" rel="noopener noreferrer" href="https://www.sciencedirect.com/science/article/pii/S0308814622016338">α- and β-bitter acids</a>, like humulones and lupulones, whose concentrations determine the final sensory profile of the beer (Figure 1).Accurately characterizing these compounds in each batch allows brewers to unlock the full potential of every variety of hops.<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_2_6435757c03.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 1. General chemical structure of hop bitter acids." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_2_6435757c03.jpeg 222w," sizes="100vw" width="700" height="493">While conventional analytical methods rely on long, manual sample preparation steps and hazardous solvents, laboratories now strive for greener and more efficient workflows.And moving from manual to online sample preparation is one of the easiest ways your lab can reduce waste and — most importantly — improve reliability with automation.<h4>Key takeaways</h4><ul><li>Online SPE reduces hands-on work, shortens turnaround time, and supports more sustainable methods by cutting solvent use and eliminating single-use cartridges.</li><li>Automated UHPLC workflows are easier for new users to execute, offering more reproducible quantifications of α- and β-bitter acids in hops.</li><li>Accurate bitter acid profiles help brewers distinguish hop varieties and control flavor with confidence.</li></ul><h4>Comparing offline vs. online solid phase extraction for bitter acid HPLC analysis</h4>If you’ve spent long hours in the lab preparing samples for hops analysis, you’re not alone.Manual sample preparation often takes the most time in hops analysis, an area where online <a target="_blank" rel="noopener noreferrer" href="https://www.thermofisher.com/content/lifetech/global/en/home/industrial/chromatography/chromatography-learning-center/chromatography-consumables/sample-prep.html">solid phase extraction</a> (SPE) can make a real difference. Here’s why.Manual SPE has a lot of manual steps. Extraction. Cartridge loading. Washing. Elution. And sometimes solvent exchange or reduction. All before your actual analysis begins. This labor-intensive workflow can take up to an hour and depends strongly on operator skillsets, making reproducibility a challenge for new hires.<h4>Online SPE analysis provides key benefits like:</h4><ul><li>Hands-off workflow free of cartridges, manifolds, or vacuum steps.</li><li>Column washing and re-equilibration occur in parallel with separation.</li><li>SPE step is complete in just two minutes.</li><li>Minimizes operator-dependent variability.</li><li>Uses less than 8 mL of solvent.</li></ul>Let’s explore what this technique looks like in practice.<h4>Online SPE for analyzing α- and β-bitter acids in hops standard solutions.</h4>Changing your sample preparation from manual to automated isn’t complicated. With the right tools you can fully integrate online SPE with your UHPLC system (Figure 2).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_3_4fb14243b4.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 2. Schematic workflow for the determination of bitter acids in hops. The process involves clean up and instrumental analysis using the Thermo Scientific Vanquish Online SPE UHPLC System." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_3_4fb14243b4.jpeg 245w," sizes="100vw" width="700" height="323"><h4>The process for analyzing a hops standard solution is straightforward:</h4><ol><li>First, extract hop samples with ethanol (a greener alternative to toluene or diethyl ether in conventional methods).</li><li>Inject the extract directly into your instrument for analysis. Bitter acids retain<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1970"> on the SPE column</a> while matrix interferences that can comprise quantitation are removed.</li><li>Next, backflush the SPE column to transfer the analytes to the<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/423"> analytical column </a>for separation. While this separation is taking place, the SPE column is washed and re-equilibrated in parallel, keeping the total run time to 15 minutes, with the separation of all six major bitter acids in a single analysis (Figure 3).</li></ol><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_4_1e47405e3c.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 3. UV chromatogram of hop bitter acids in standard solution (1-cohumulone, 2-humulone, 3-adhumulone, 4-colupulone, 5-lupulone, 6-adlupulone)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_4_1e47405e3c.jpeg 245w," sizes="100vw" width="700" height="347"><h4>Online SPE for analyzing α- and β-bitter acids in real hops samples</h4>Analytical labs need methods that are accurate and reliable for brewers to develop distinct and reproducible flavor profiles across batches.To assess the applicability of online SPE UHPLC methods for hops analysis, we analyzed bitter acid profiles from four species — Sultana, Barbe Rouge, Azacca, and Sabro.The concentration of α-acids dominated all samples, while each hops species exhibited distinct profiles in terms of α-acid and β-acid content, making them suitable for different brewing strategies (Figure 4).<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_5_3a179217db.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 4. Bitter acid profiles in four different hop species, error bars display SD (n=6). To check method consistency, we measured each hops extract six times. Variation between measurements was low, with relative standard deviation below 3.5 % across all hops species." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_5_3a179217db.jpeg 245w," sizes="100vw" width="700" height="410"><ul><li>For testing labs, this process translates into a workflow that is easy to run, fast, and delivers reliable results without added complexity.</li><li>For craft brewers, reliability means clear, trustworthy insights into hops bitter acid profiles, for better hop selection and more precise control of bitterness and flavor in your beer.</li></ul><h4>From carefully procured samples to tasty sips</h4>Efficient UHPLC workflows support faster results, less solvent use, and reliable bitterness data for brewers. And online SPE turns those advantages into practical, day-to-day benefits for brewers and labs alike.<ul><li>Less hands-on skills required for lab analysts</li><li>Faster results from labs to brewers</li><li>A more sustainable way to work</li><li>Clear insights into hops flavor</li></ul>To learn more about the method and see the full application data, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/cn_004238_hplc_vanquish_online_spe_bitter_acids_hops_cn004238_na_en_587a5d300b.pdf">check out our application note today</a>.<h4>FAQs</h4><div><div><h5>What are the key compounds in hops analyzed by HPLC?</h5>Bitter acids, namely α-acids and β-acids, especially the six major bitter acids (humulones and lupulones) that define hop bitterness and are required for quality control and brewing decisions.</div><div><h5>What column types are recommended for hop acid separations?</h5>Classical C18 Silica columns are ideal for bitter acids separation. UHPLC compatible columns with particle size ≤ 2 µm boost analysis with higher flow rate, thus shorter analysis time and solvent consumption.</div><div><h5>What’s the best workflow for hops analysis?</h5>A typical workflow for hop analysis consists of three main steps: extraction of the target compounds, clean-up of co-extracted matrix components, and instrumental analysis by HPLC or UHPLC. To keep this workflow efficient and reproducible, you should minimize manual handling and add in automation when possible. Integrating online SPE into your LC instrument allows sample clean-up to run automatically, reducing hands-on time, solvent use, and variability while delivering faster, more reliable results.</div></div><blockquote>Visit us on&nbsp;<a target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/showcase/72003132/admin/dashboard/">LinkedIn:</a>&nbsp;#UHPLC #Automation</blockquote></div></div>

How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors

In the week of June 29, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.<blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars">👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</a></h4>👉 Search and filter in the largest global database with over 5 500 GC, LC, MS and spectroscopy webinars.</blockquote><h5>1. Thermo Fisher Scientific: Insights from an IC specialist: To be suppressed or not suppressed?</h5><ul><li>Tu, 30.6.2026 09:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6310">Registration</a></li></ul>Join Thermo Fisher’s Ask the Experts session to learn how suppressor technology impacts ion chromatography performance, sensitivity, reliability, maintenance, and troubleshooting.<h5>2. SCIEX: Advancing Proteomics with ZenoTOF: From Single-Cell Analysis to Plasma Biomarker Discovery</h5><ul><li>Tu, 30.6.2026 11:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6311">Registration</a></li></ul>Discover how ZenoTOF high-resolution mass spectrometry is accelerating single-cell proteomics and plasma biomarker discovery through enhanced sensitivity, throughput, and automation.<h5>3. Agilent Technologies: Measuring Diverse Samples with UV/VIS Spectrometers and Integrating Spheres</h5><ul><li>Tu, 30.6.2026 20:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6052">Registration</a></li></ul>This webinar will discuss diffuse transmission and reflection UV/VIS measurements, including how to perform measurements with Agilent’s Cary 60 UV/VIS Spectrometer.<h5>4. Waters Corporation: Informatics series #33 Tips, Tricks and Best Practices</h5><ul><li>Th, 2.7.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6315">Registration</a></li></ul>This interactive session revisits essential features, shortcuts, and practical techniques in Empower software that can streamline everyday laboratory work and reduce unnecessary effort.<h5>5. Waters Corporation: Unlocking Therapeutic Peptide Characterisation (GLP-1RAs) with Cyclic IMS</h5><ul><li>Th, 2.7.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6313">Registration</a></li></ul>Discover how cyclic ion mobility spectrometry (cyclic IMS) improves characterization of GLP-1 analogues and therapeutic peptides, supporting development, quality control, and regulatory submissions.<h5>6. Agilent Technologies: Spectral Flow Cytometry Masterclass - Session 1</h5><ul><li>Fr, 3.7.2026 07:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6316">Registration</a></li></ul>Learn how full-spectrum flow cytometry enables high-dimensional cell analysis. Explore spectral flow technology, experimental design, and applications in immunology, oncology, and vaccine research.

Webinars LabRulezLCMS Week 27/2026

The international standard ISO/IEC 17025 [1] clause 7.7.2 with regards to ensuring the validity of results, requires a laboratory to participate in proficiency testing (PT) and/or to participate in interlaboratory comparisons (ILCs) other than PT. However, no guidance as to what these other ILCs might be, or indeed how they might compare in relation to PT, is provided. This leaflet aims to outline other ILCs available, pointing out some of the limitations as compared to PT.&nbsp;There are three major types of ILCs in which a group of laboratories analyses identical portions from a homogeneous, stable test sample, with each type being characterized by its intended purpose [2,3]:<img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_2_d9263807fb.jpg" alt="Eurachem: Interlaboratory comparisons other than proficiency testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_2_d9263807fb.jpg 245w," sizes="100vw" width="1507" height="607">A key point is that PT is an ILC that is designed to specifically evaluate the performance of participants, providing them with an infrastructure to monitor and assess the validity of their results. This is not the key purpose of the two other ILCs, and thus depending on their intended purpose they have a number of limitations that laboratories need to be aware of when using them rather than PT. Only proficiency testing should have been conducted in full compliance to the competency standard ISO/IEC 17043 [4].&nbsp;<h4>Evaluation of measurement procedure performance&nbsp;</h4>These ILCs, are designed to assess how a particular measurement procedure performs and whether it is fit for its intended purpose. These ILCs are often referred to as a ‘method performance study’ or a ‘collaborative study’ [2]. Some limitations of using such ILCs for monitoring laboratory performance as an alternative to PT are:&nbsp;<ul><li>All participants use the same measurement procedure i.e. the measurement procedure that is being validated. Unless the measurement procedure is being routinely used by the participating laboratory such an ILC will not assess the routine performance of the laboratory using their own routine measurement procedure. Nor does it enable them to compare their performance with other laboratories using alternative measurement procedures.&nbsp;</li><li>The measurement procedure is likely to be new, so participants may not have established stable procedures and quality control, so performance may not reflect routine use.&nbsp;</li><li>The report from such an ILC would not provide information on the performance of the participant, if the statistical model used makes the assumption that all laboratories perform with equal variability.</li><li>The design of the study may require the participants to assess multiple samples and/or to undertake multiple replicate analysis on the test materials. This may not be representative of the routine measurements or tests undertaken by the laboratory.&nbsp;</li><li>The conclusion of the ILC might be that the measurement procedure being assessed is not valid.&nbsp;</li></ul><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_3_a53ecd2f5d.jpg" alt="Eurachem: Interlaboratory comparisons other than proficiency testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_3_a53ecd2f5d.jpg 157w," sizes="100vw" width="570" height="566"><h4>Characterisation of candidate reference materials&nbsp;</h4>These are ILCs that assign a property value to a candidate reference material, usually with a stated measurement uncertainty. These are often referred to as a ‘material certification study’ [2]. Limitations of using such ILCs as an alternative to PT are:&nbsp;<ul><li>The analysis of the candidate reference material is likely to require additional care in exercising the routine measurement procedure, such as substantially more replication, and/or may require quite different reporting formats (e.g. all valid replicates instead of a mean result). Thus, such an ILC will not necessarily provide an evaluation of the performance of the laboratory based on the routine use of their measurement procedures.&nbsp;</li><li>The report from such an ILC may include the results from the participating laboratories but would not provide information on the performance of each laboratory.&nbsp;</li><li>Participating laboratories may be required to assess multiple samples and/or to undertake multiple replicate analysis on the candidate reference materials. Thus this may not be representative of the routine measurements or tests undertaken by the laboratory.&nbsp;</li></ul><h4>Other ILCs&nbsp;</h4>Some other ILCs, whilst not being conducted in full compliance of the requirements of ISO/IEC 17043, may be designed to evaluate participant performance. These would include small ILCs as defined by EA‑2/21 [5] or split sample ILCs i.e. where a portion of a single sample is sent to two or three laboratories. Whilst these ILCs are specifically designed to evaluate participant performance, they may not provide a comprehensive comparison that a PT might provide. In such cases the laboratory needs to evaluate carefully the competence of the organization managing the ILC and the suitability of the service externally provided (ISO/IEC 17025 clause 6.6).

Interlaboratory comparisons other than proficiency testing

Article

Webinars

Academy

A unique company dedicated to serving science helping our customers drive productivity and accelerate results. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Thermo Fisher Scientific

Eurachem is a European network promoting international traceability of chemical measurements and good analytical practice. It provides expert guidance, supports method validation, uncertainty evaluation, proficiency testing, and facilitates discussion on technical and policy issues in analytical quality.

Eurachem

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

Separation Science

Agilent Technologies

Shimadzu Corporation

SCIEX

Waters Corporation

<h3>Solving Problems That Matter - a Waters webinar series featuring USP speakers</h3><h4>Episode 9: Nitrosamines</h4>When present in pharmaceutical products, nitrosamine impurities - a probable carcinogen - can disrupt drug supply chains and lead to shortages resulting from product recalls and withdrawals.Join our panelists Naiffer Romero from the USP and Marian Twohig from Waters Corporation as they address analytical challenges in the detection and control of nitrosamines and Nitrosamine Drug-Substance Related Impurities (NDSRIs).Key learning objectives:<ul><li>Understand the current analytical challenges associated with the detection and control of nitrosamine impurities. Explore fit-for-purpose and compliant-ready LC-MS-MS solutions for the cGMP laboratory.</li></ul>Who should attend:<ul><li>Pharmaceutical scientists involved with the detection and control of nitrosamines impurities</li></ul><blockquote>Presenter: Naiffer Romero, MSc, MPH (Principal Scientist - Scientific Affairs, US Pharmacopeia)</blockquote><blockquote>Naiffer has more than 20 years of pharmaceutical industry experience. In his 13+ years tenure with USP, he has served several roles: Lead scientist in the dosage form performance laboratory, reference standard development team, Manager in charge of LATAM Compendial engagement and education, responsible for stakeholders and national regulatory bodies engagement. Naiffer is also a certified USP Education instructor. Most recently, Naiffer joined USP's Scientific Affairs performance cell, where he leads scientific outreach and engagement for LATAM &amp; U.S. on key national health priority topics. His combined pharmaceutical expertise includes Analytical Development, salt and polymorph selection, Development of dissolution methods, IVIVC modeling, and impurity analytical strategy. Naiffer also serves as a member of USP's Nitrosamine Steering Committee and community host to 'Nitrosamine Exchange,' a knowledge community in All-things Nitrosamine. Naiffer also liaises technical discussion on pharmacopeial collaboration, including international meetings of World Pharmacopeias (part of WHO).</blockquote><blockquote>Presenter: Marian Twohig, Ph.D. (Consultant Scientist, Waters Corporation)</blockquote><blockquote>Marian has over 20 years of experience supporting quantitative and qualitative applications in the pharmaceutical, food and environmental and materials science industries. She works as a Consultant Scientist for Waters Corporation where she has previously held several Senior Scientist positions. Currently, the focus of Marian’s work is in the development of quantitative analytical methods to meet the needs of the pharmaceutical industry. She is particularly interested in chromatographic separations and the application of combining low- and high-resolution mass spectral data with other chemical information for identification of unknown chemical entities. Marian holds a Ph.D. in Analytical Chemistry from Munster Technological University, Cork, Ireland.</blockquote><blockquote>Moderator: Isabelle Vu Trieu (Pharmaceutical Market Development Manager, Americas, Waters Corporation)</blockquote><blockquote>Isabelle is a business development professional dedicated to delivering benefits to analytical scientists in the life sciences industry. With over 20 years of experience in providing chromatography and mass spectrometry solutions, Isabelle is particularly interested in helping pharmaceutical scientists achieve the data quality and integrity needed to drive decisions for drug quality, safety and efficacy. Isabelle joined Waters in 2009 and currently manages the development of the pharmaceutical market in the Americas. She holds Masters’ degrees in Chemistry from Columbia University and the University Claude Bernard in Lyon, France as well as a Chemical Engineering degree from Ecole Supérieure de Chimie Physique Electronique in Lyon, France.</blockquote>

Waters Corporation: Solving Problems That Matter - a Waters webinar series featuring USP speakers

Nitrosamines

This webinar will address analytical challenges in the detection and control of nitrosamines and Nitrosamine Drug-Substance Related Impurities (NDSRIs).

<h4>Virtual event: Pharma conclave series 2024</h4>SCIEX offers the platform for the experts to take the stage and drive technological progressWelcome to Pharma conclave series 2024 – where our customers’ expertise meets innovation, transforming your knowledge and empowering you to revolutionize your work processes. Join us in discovering techniques that will enhance your skills to accelerate your daily operations in the development of new drugs.From the research of new markers to the drug development moving into non and GLP bioanalysis. Confidently plan your next lab expansion with the knowledge gained from industry leaders and pioneers.<ul><li>May 16 Event 1: Pharma omics</li><li>September 17 Event 2: Impurities</li><li>October 23-24 Event 3: Pharma</li></ul>10:00 a.m.–12:00 p.m. CET<h3>Event 3: Pharma</h3>The pharma connectionFrom discovery to QA/QC. All the process to bring a new treatment to the patients is following a path to connect the different stages until the magic happens.Join to see how the scientists are generating the needed tricks to connect the initial though with the final formulation.<h3>Day 1</h3><h5>10:00 - 10:30 - Metabolomics screening kits for use in clinical trials</h5><ul><li>Heike Wiese, Nuvisan</li></ul><h5>10:30 – 11:00&nbsp;- Sphingolipid biomarkers in neurodegenerative drug development</h5><ul><li>Jose Carlos Gonzalez, AMSbiopharma</li></ul><h5>11:00 – 11:30 - Parallel setup of a series of micro LC methods, coupled with the low-resolution mass spec (API7500) for &nbsp;TG2 inhibitors</h5><ul><li>Davide Massari and Chiara Olmi, ERBC Group</li></ul><h5>11:30 – 12:00&nbsp;- PFAS analysis and mass spectrometry: Beyond environmental, food and packaging. What about cosmetic and pharmaceutical products?</h5><ul><li>Emiliano De Dominicis, Merieux</li></ul><blockquote>Presenter: Bruno Manadas, PhD</blockquote><blockquote>Dr Manadas is a prominent Cell Biology researcher at CNC-UC since 2017. With expertise in biochemistry, psychology, and biotechnology, he's authored 130+ publications and led multiple projects. As head of CNC's Mass Spectrometry node and Associate Editor for Frontiers, he's contributed significantly to neuroscience and psychiatry. Bruno's research focuses on cell biology mechanisms, translational biomarker research, and MS-based approaches for studying protein oxidation. He played a pivotal role in establishing the hospital biobank and teaches at the Portuguese Catholic University.</blockquote><blockquote>Presenter: Dorte Bekker-Jensen</blockquote><blockquote>Dorte is heading the Applications Development team in Proteomics Research at Evosep. She has long-term experience within proteomics and has focused on technology development by developing simple and automated workflows for high-throughput applications.</blockquote><blockquote>Presenter: Stefan Ledinger</blockquote><blockquote>Stefan has 20 years of experience in the life sciences and diagnostic industries. For the last dozen years, he has been serving various functions within biocrates life sciences ag. Most recently, he has been responsible for the market development for metabolomics solutions in the pharmaceutical and biotech industries. He currently serves as Global Head of Sales. Stefan holds degrees in business administration and bioengineering, combining commercial know-how with a passion for science.</blockquote><blockquote>Presenter: Markus Langsdorf</blockquote><blockquote>Markus has 14 years of experience in life sciences industries. As he joined biocrates in 2010, he worked for 11 years as application support specialist for biocrates’ metabolomics profiling solutions. 3 years ago he changed his position withing the company to his new function as product manager. Markus studied chemistry and graduated with a PhD in Analytical Chemistry.</blockquote>

Pharma conclave series 2024: Pharma (Day1)

From discovery to QA/QC. The process to bring a new treatment to the patients.

<h4>Virtual event: Pharma conclave series 2024</h4>SCIEX offers the platform for the experts to take the stage and drive technological progressWelcome to Pharma conclave series 2024 – where our customers’ expertise meets innovation, transforming your knowledge and empowering you to revolutionize your work processes. Join us in discovering techniques that will enhance your skills to accelerate your daily operations in the development of new drugs.From the research of new markers to the drug development moving into non and GLP bioanalysis. Confidently plan your next lab expansion with the knowledge gained from industry leaders and pioneers.<ul><li>May 16 Event 1: Pharma omics</li><li>September 17 Event 2: Impurities</li><li>October 23-24 Event 3: Pharma</li></ul>10:00 a.m.–12:00 p.m. CET<h3>Event 3: Pharma</h3>The pharma connectionFrom discovery to QA/QC. All the process to bring a new treatment to the patients is following a path to connect the different stages until the magic happens.Join to see how the scientists are generating the needed tricks to connect the initial though with the final formulation.<h3>Day 2</h3><h5>10:00 - 10:30&nbsp;- Metabolomics: From target engagement to metabolic phenotyping. Applications in drug discovery</h5><ul><li>Filippos Michopoulos, Astrazeneca</li></ul><h5>10:30 - 11:00&nbsp;- Development of an LC-MS Method to Quantify Endogenous Urea in Mouse Plasma and BAL.</h5><ul><li>Benjamin Smith, Cyprotex</li></ul><h5>11:00 - 11:30&nbsp;- Optimization of extraction &amp; LC-MS conditions for the bioanalysis of antibody drug conjugates with diverse chemistries</h5><ul><li>John Perkins, KCAS</li></ul><h5>11:30 - 12:00&nbsp;- Preparation of rodent whole blood and plasma microsamples for LC-MS/MS bioanalysis in toxicology studies</h5><ul><li>Birgitte Støvring, Scantox</li></ul><blockquote>Presenter: Bruno Manadas, PhD</blockquote><blockquote>Dr Manadas is a prominent Cell Biology researcher at CNC-UC since 2017. With expertise in biochemistry, psychology, and biotechnology, he's authored 130+ publications and led multiple projects. As head of CNC's Mass Spectrometry node and Associate Editor for Frontiers, he's contributed significantly to neuroscience and psychiatry. Bruno's research focuses on cell biology mechanisms, translational biomarker research, and MS-based approaches for studying protein oxidation. He played a pivotal role in establishing the hospital biobank and teaches at the Portuguese Catholic University.</blockquote><blockquote>Presenter: Dorte Bekker-Jensen</blockquote><blockquote>Dorte is heading the Applications Development team in Proteomics Research at Evosep. She has long-term experience within proteomics and has focused on technology development by developing simple and automated workflows for high-throughput applications.</blockquote><blockquote>Presenter: Stefan Ledinger</blockquote><blockquote>Stefan has 20 years of experience in the life sciences and diagnostic industries. For the last dozen years, he has been serving various functions within biocrates life sciences ag. Most recently, he has been responsible for the market development for metabolomics solutions in the pharmaceutical and biotech industries. He currently serves as Global Head of Sales. Stefan holds degrees in business administration and bioengineering, combining commercial know-how with a passion for science.</blockquote><blockquote>Presenter: Markus Langsdorf</blockquote><blockquote>Markus has 14 years of experience in life sciences industries. As he joined biocrates in 2010, he worked for 11 years as application support specialist for biocrates’ metabolomics profiling solutions. 3 years ago he changed his position withing the company to his new function as product manager. Markus studied chemistry and graduated with a PhD in Analytical Chemistry.</blockquote>

Pharma conclave series 2024: Pharma (Day 2)

This webinar will guide you through optimizing your Q-TOF for superior data quality by selecting the most suitable tune mode for your samples.We will delve into various MS acquisition modes, including MS only, All Ions (QRAI), Auto MS/MS (directed MS/MS; targeted MS/MS), and PRM mode.Learn how to fine-tune method settings to enhance your data quality and achieve the best analytical results. Whether you’re a seasoned user or new to QTOF, this session will provide valuable insights to elevate your mass spectrometry.<blockquote>Presenter: &nbsp;Stefan Schaebler (Application Specialist LC/MS, Agilent Technologies)Stefan completed his PhD in Biology, specializing in LC-MS-based lipidomics and metabolomics. Following his doctoral studies, he joined Agilent Technologies as an LC/MS Application Specialist. In this role, Stefan focuses on small molecule applications using LC-QTOF, with a strong emphasis on software tools and data interpretation.</blockquote>

Agilent Technologies: MassHunter Masterclass Months

MassHunter Acquisition Q-TOF Part II – Advance Settings

Join us for an in-depth exploration of advanced settings in MassHunter Acquisition for Q-TOF systems.

This webinar will guide you through optimizing your Q-TOF for superior data quality by selecting the most suitable tune mode for your samples.You will learn about the different optimisation workflows available within MassHunter Acquisition, including how to optimise Multiple Reaction Monitoring (MRM) methods for new compounds. We will also review key tools for creating and editing worklists, and discuss the benefits of Intelligent Reflex tools, demonstrating how they can be effectively implemented in your workflows.This webinar is designed to enhance your understanding and application of MassHunter Acquisition, ensuring you can achieve optimal performance in your analytical processes.<blockquote>Presenter: Day Powell (Field Application Specialist, Agilent Technologies)Day has worked for Agilent as an Environmental Application Specialist for over a year, before this he worked for United Utilities (UU) as a Technical Specialist responsible for developing new methodologies for both LC/MS and GC/MS applications. Day has worked with PFAS for several years and helped UU to UKAS accredit a novel method for 47 PFAS in drinking water using direct injection to address the latest DWI regulations. Presenter: Jonathan Spencer (Application Specialist, Agilent Technologies)Jonathan studied BSc Natural Sciences at the University of Nottingham and later went on to Sheffield Hallam University to study a MSc in Forensic Science.Following graduation, he spent 2 years as a Confirmatory Analyst in an anti-doping and forensic toxicology lab, before joining Agilent as an LC/MS Applications Scientist. At Agilent, he focuses on small molecule applications using LC/TQ and LC/Q-TOF in fields of like food, forensic and environmental analysis.</blockquote>

MassHunter Acquisition for LC/TQ and MRM Method Optimisation

This session will provide a comprehensive overview of the various aspects of MassHunter Acquisition for Liquid Chromatography/Triple Quadrupole (LC/TQ) systems.

Measurement of FT4 and FT3 is typically performed by immunoassay, however these can be prone to suffer from interferences and a lack of selectivity. Currently, the accepted gold standard for the measurement of FT4 and FT3 is using equilibrium dialysis (ED) and combined with the use of LC-MS/MS can overcome the issues with immunoassay in the measurement of FT4 and FT3. However, the equilibrium dialysis procedure can be quite time consuming and often being performed overnight.Here, we describe a simple clinical research method to perform ED using a commercially available device followed by sample preparation by solid phase extraction (SPE) and UPLC-MS/MS analysis using the Waters™ ACQUITY™ UPLC and analytically sensitive Xevo™ TQ Absolute Mass Spectrometer for clinical research. Data analysis and review has been simplified with the use of the waters_connect™ with QUAN Review Software. This has allowed for the complete workflow including equilibrium dialysis to be performed within a typical working day.Simplified Equilibrium Dialysis for the UPLC-MS/MS Analysis of Free Testosterone (FT) for Clinical ResearchHistorically, the measurement of free testosterone in human serum has presented a challenge for laboratory scientists, with such a large portion bound and the complexity and time involved in “gold standard” equilibrium dialysis. With a simple, fast, workflow combined with the analytical sensitivity afforded by the Waters Xevo™ TQ Absolute Mass Spectrometer, a newly developed, precise, accurate and selective clinical research method will be presented.<blockquote>Presenter: Robert Wardle (Senior Clinical Scientist, Waters Corporation)Robert Wardle is currently a Senior Scientist employed at Waters Corporation in Wilmslow, UK, performing research and development of applications and products for Clinical Research. His primary area of research is vitamins and in particular vitamin D metabolites, steroid hormones and in-depth knowledge of offline and online automation.Robert joined Waters in 2010 as a Clinical Validation Scientist, playing a key role in verification activities for the MassTrak XE Immunosuppressants kit available in the EU. He moved into his current role as a Senior Scientist in 2013, where he developed clinical research methods for a range of applications including vitamin D metabolites, estrogens, a large panel of steroid hormones and more recently this application on free T4 and free T3.Presenter: Stephen Balloch (Senior Clinical Scientist, Waters Corporation)Stephen Balloch graduated from the University of York (UK) with a Master’s degree in Chemistry, which included a strong focus on analytical chemistry. Subsequently he worked as a laboratory scientist in a GLP compliant research facility, progressing to Study Director. And, since 2010, he has been part of the clinical team at Waters (Wilmslow, UK). His principal focus has been on the development and validation of bioanalytical methods according to CLSI guidelines, with a focus on therapeutic drug monitoring. Additionally, he has supported newborn screening, vitamin and steroid analysis, including this clinical research method for free testosterone</blockquote>

Free Testosterone and Free T3/T4

Simplified Equilibrium Dialysis and SPE Method for the UPLC™-MS/MS Analysis of Free Thyroxine (FT4) and Triiodothyronine (FT3) for Clinical Research.

Join us for an enlightening Digital Classrooms session focused on the pivotal advancements in mass spectrometry (MS) technology and its applications in personalized health monitoring, early disease detection, and critical care management.This session, led by esteemed experts Dr. Naatasha Isahak and Dr. Abhik Banerjee, Zonal Technical Chief of Apollo Diagnostics' East Zone, will uncover how MS is transforming modern healthcare.Explore how MS technology facilitates the quantification of vitamins, hormones, metabolites, and proteins, providing insights into metabolic health, nutritional status, and organ function. Additionally, through real-world case studies, learn how MS is utilized for rapid diagnosis and therapeutic monitoring in acute conditions, such as sepsis and organ failure.Don’t miss this opportunity to understand the technical aspects of MS-based assays, as well as practical considerations for integrating these tools into clinical workflows for enhanced patient outcomes. Whether you are involved in clinical diagnostics or health management, join us to discover the expanding influence of mass spectrometry in today’s healthcare landscape.<h5>Learning Objectives:</h5><ul><li>Delve into the latest advancements in MS technology and its applications in personalized health monitoring, early disease detection, and critical care management.</li><li>Discover how MS quantifies biomarkers like vitamins, hormones, metabolites, and proteins, and its role in assessing metabolic health, nutritional status, and organ function.</li><li>Gain practical insights into seamlessly integrating MS-based assays into clinical workflows, with real-world case studies demonstrating its effectiveness in rapid diagnosis and therapeutic monitoring of acute conditions like sepsis and organ failure.</li><li>Explore a concise overview of Shimadzu's innovative solutions tailored for wellness diagnostics and critical care applications.</li></ul><blockquote>Presenter: Dr. Abhik Banerjee (Zonal Technical Chief, East Zone, Apollo Diagnostics)Dr. Abhik Banerjee is a highly accomplished pathologist with over 11 years of post-MD pathology experience and more than a decade as a Consultant Pathologist. He currently serves as the Zonal Technical Chief for East Zone at Apollo Diagnostics, overseeing the operations of around 30 laboratories in East India. A specialist in laboratory medicine, pathology, and quality control, Dr. Banerjee has spearheaded the establishment of the first LC-MS/MS (Tandem mass spectrometry) setup in Eastern India at Suraksha Diagnostics, Kolkata. He has held leadership roles such as Lab Director and Chief of Quality at Suraksha Diagnostics' COVID-19 Cell, and was the Nodal Officer for the only CAP-accredited medical laboratory in East India. He has contributed to the field with publications in national journals and received the Dx Leadership Award in 2019. Additionally, Dr. Banerjee is a certified lead assessor for CAP audits, has extensive experience with NABL and ISO 15189 audits, and has been an active speaker and reviewer for medical journals.Presenter: Naatasha Isahak (Market Specialist (Clinical and Forensics), Shimadzu (Asia Pacific) Pte Ltd)Naatasha Isahak is a Product Specialist for MALDI and Life Sciences Products from Shimadzu Asia Pacific Pte Ltd. She has received her PhD from the University of Sydney (Chemistry) working on surface initiated polymerisation on silica nanoparticles using RAFT polymerisation and bioorthogonal conjugation of peptides using Native Chemical Ligation. She then spent 5 years working on developing platforms for stem cells and organoids characterization that included working with microfluidic devices and helical polymers. Naatasha joined Shimadzu in 2022 to expand her experiences to MALDI characterization on materials and biological samples.</blockquote>

Shimadzu: Wellness Diagnostics And Critical Care

Wellness Diagnostics And Critical Care

We will uncover how MS is transforming modern healthcare.

<div><div>Therapeutic synthetic oligonucleotides represent unique analytical challenges in late-stage development. To meet the stringent regulatory requirements, highly specific and sensitive methods such as liquid chromatography-mass spectrometry (LC/MS) must be used. However, neither chromatography nor mass spectrometry data systems have the capabilities, both in function and in data integrity, for the typical QC analyst end user to run a highly complex method such as purity, assay, and impurity profiling for therapeutic oligos such as anti-sense oligonucleotides.In this presentation, we present a paradigm shift in software with Oligo Analysis Accelerator for OpenLab CDS. This application streamlines the analytical workflow by using a fit-for-purpose user interface while leveraging existing data integrity and compliance architecture within OpenLab CDS.<h4>By attending this webinar, you will:</h4><ul><li>Understand the fundamentals of ion-pair reversed-phase LC/MS for oligonucleotides</li><li>Discover how a single quadrupole detector is used for impurity profiling of anti-sense oligonucleotides</li><li>Learn how fit-for-purpose software for LC/MS analysis in QC lot release can save time and enhance quality</li></ul><h5>Who should attend</h5><ul><li>Analytical chemists interested in cutting-edge software for large molecule late-stage development</li><li>Analytical research and development labs interested in developing robust methods for single-stranded oligo therapeutics</li><li>Process scientists who rely on in-process control purity results to optimize synthesis and purification for oligos</li><li>Quality assurance and quality control personnel supporting oligo testing labs</li></ul><blockquote>Presenter: Brian Rivera (Software Product Manager, Agilent Technologies)Brian Rivera is a software product manager at Agilent Technologies with 20 years of experience in HPLC analysis of large molecules.</blockquote></div></div>

Separation Sciences: Boost Efficiency in Oligonucleotide QC with Software Designed for the Job

Boost Efficiency in Oligonucleotide QC with Software Designed for the Job

In this presentation, we present a paradigm shift in software with Oligo Analysis Accelerator for OpenLab CDS.

Oligonucleotide QC with Software Designed for the Job

In this webinar, Dr Stuart Best, Deputy Director, Drug Metabolism and Pharmacokinetics (DMPK), Sygnature Ltd, will provide an overview of analytical approaches in Discovery Bioanalysis CNS measurement, to deliver more information from lower sample volume and align with the 3R principles.Drug discovery programs that target the Central Nervous System require bioanalytical measurement of test compounds and neurotransmitter concentrations to establish a pharmacokinetic-pharmacodynamic (PK-PD) relationship. Bioanalytical assessment of unbound compounds in blood, brain tissue, and cerebrospinal fluid describes its distribution for the systemic circulation into the CNS. The inherently high sensitivity and specificity of LC-Triple Quadrupole Mass Spectrometry enables low level detection in small sample volumes, allowing serial sampling from single animals, reducing animal use and inter-animal variability, supporting the 3Rs principles (replacement, reduction, refinement)The bioanalysis of neurotransmitters such acetylcholine and monoamines, is challenging due to low molecular weight, high polarity, instability, and low endogenous concentrations. At Sygnature, the in vivo Pharmacology team employ microdialysis to permit assessment of neurotransmitter changes in specific brain regions. The low endogenous concentrations in brain regions and collection through dialysis probe into artificial CSF lowers further quantitation limits for neurotransmitter detection and lead to the requirements for highly sensitive and specific analytical approaches.This presentation will describe the above approached to CNS measurement and how LC-Triple Quadrupole Mass Spectrometry enables Sygnature scientists to align to the 3R principles and maximize data output from small samples and relate test compound concentrations to neurotransmitter changes. Truly, achieving on the concept of ‘More from Less’ Stuart will also present further refinement models for assessing test compound impact on acetylcholine and enabling more physiologically relevant measurements.<h4>Key Learning Objectives:</h4><ul><li>Understand the challenges as CNS measurements of test compounds and neurotransmitter concentrations to establish PK-PD relationships</li><li>Explore the complexities of neurotransmitter bioanalysis in discovery DMPK due to low concentrations and instability</li><li>Learn the roles of LC-Triple Quadrupole Mass Spectrometry enabling sensitive detection in small samples and alignment to the 3Rs (replacement, reduction, refinement) principles</li></ul><div><blockquote>Presenter: Dr Stuart Best (Deputy Director, DMPK, Sygnature Ltd)Dr Best's expertise spans regulated and discovery bioanalysis and discovery DMPK, from supporting DMPK screening (solubility, log D, metabolic stability, permeability, plasma protein binding, etc) through in vivo assessment of compounds to more detailed profiling to support candidate nomination and human dose prediction, including the assessment of potential risk from drug-drug interactions.During his time in the industry Dr Best has expanded the utilisation of mass spectrometry (specifically triple quadrupole LC-MS/MS) to help solve drug discovery project challenges with a strong focus on maximizing data capture from in vivo samples, refining experimental designs to permit better PD endpoints and expanding LC-MS/MS support for biological screening assays, where a mass spectrometry end-point is required, for the measurement of more challenging endogenous analytes.</blockquote></div>

More from less: LC-MS/MS an Enabling Technology to Maximize Bioanalytical Data Collection from Small Sample Volumes

An overview of analytical approaches in Discovery Bioanalysis CNS measurement, to deliver more information from lower sample volume.

LC-MS/MS to Maximize Bioanalytical Data Collection

Biotherapeutics offer targeted therapies for treating a wide range of diseases with greater specificity and efficacy. However, unlike traditional small-molecule drugs, biotherapeutics are typically larger and more complex, requiring advanced techniques for their production, purification, and characterization.Therapeutic proteins, first introduced many years ago, have continually advanced in complexity. Since the introduction of monoclonal antibodies, we now have antibody drug conjugates, bispecific antibodies, fragments and fusion proteins, all of which are in various stages of development.&nbsp;To keep pace with biotherapeutics advances, analytical techniques must also advance.&nbsp;<h5>In this webinar, we will present chromatography findings on:</h5><ul><li>New workflows for intact and peptide mapping characterization of proteins</li><li>Advanced column chemistries for charge variant analysis with pH and salt gradients&nbsp;</li><li>Rapid desalting SEC column for high throughput analysis, ADC analysis with HIC and reversed phase chemistries</li><li>New digestion workflows coupled to a new peptide mapping column for sequence verification and post translation modification analysis</li></ul>This live webinar will be an excellent opportunity to boost your R&amp;D capabilities and strengthen your QC analytical methods for the characterization of biotherapeutics and gene therapies. Dr. Ken Cook will be presenting and answering your questions live.With over 20 years of innovation, Thermo Fisher Scientific is a leader in biomolecule separation and characterization, supported by a wealth of published research.Who should attend?&nbsp;<ul><li>Pharmaceutical and Biotech Researchers: Researchers involved in the development and characterization of biotherapeutics and gene therapies, including those working with therapeutic proteins.</li><li>Quality Control (QC) Analysts: Analysts responsible for ensuring the quality and consistency of biotherapeutic products, who will benefit from advanced methods in characterization and validation.</li><li>&nbsp;R&amp;D Managers: Managers who oversee research and development teams working with biotherapeutics, looking to enhance their workflows and methodologies.</li></ul><blockquote>Presenter: Dr. Ken Cook (Application Scientists Manager, Thermo Fisher Scientific)Dr. Ken Cook began his career in academia as a Biochemistry lecturer focused on protein chemistry and metabolism. With over 30 years of industry experience at Dionex, and later Thermo Fisher Scientific, his vast knowledge supporting and developing solutions within chromatography has established him as a bio-separations expert.Currently, Dr. Cook focuses on supporting and developing solutions for bio-pharmaceutical applications, particularly in the characterization of protein and oligonucleotide-based biotherapeutics. His work involves ongoing collaborations with both the biopharmaceutical industry and academic institutions.His expertise includes peptide mapping using LC/HRMS, charged variant analysis with novel MS coupling, glycan analysis, aggregate analysis, and on-line process monitoring. He also has a growing interest and notable success in gene therapy characterization.Given his immense experience, it is an honour to have Dr Cook share his knowledge.</blockquote>

Thermo Fisher Scientific: Innovations in Protein Characterization

Innovations in Protein Characterization

Boost your R&D capabilities and strengthen your QC analytical methods for the characterization of biotherapeutics and gene therapies.

LCMS webinars focusing on LC/MS/MS - page 41